Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC future for canker sore patch?

This article was originally published in The Tan Sheet

Executive Summary

Oral canker sore delivery vehicle OraDisc A, "which adheres to the disease site and slowly degrades, releasing the drug locally," eventually could be marketed OTC, Access Pharmaceuticals says. Although firm has been in negotiations with "numerous consumer/pharmaceutical organizations globally" to develop OTC version of oral delivery vehicle for amlexanox, details and timing of such a move remain uncertain, Access says. Final Phase III study for Rx version "has commenced and completion is anticipated by the end of 2002," company notes...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094396

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel